3000 Participants Needed

Ion Endoluminal System for Lung Cancer

Recruiting at 16 trial locations
HG
LS
LS
LS
Overseen ByLindsay Spotanski, BSc, CCRP
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Intuitive Surgical
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial examines the effectiveness of the Ion Endoluminal System, a medical device, in everyday settings for locating or biopsying lung lesions (abnormal tissue). The focus is on its performance during real-world procedures. Individuals needing a planned lung lesion biopsy and able to follow study instructions may be suitable candidates for this trial. As a Phase 3 trial, it represents the final step before FDA approval, offering participants the opportunity to contribute to the validation of a potentially groundbreaking medical device.

Do I need to stop my current medications for the trial?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What prior data suggests that the Ion Endoluminal System is safe for pulmonary lesion localization or biopsy?

Research has shown that the Ion Endoluminal System, used for lung biopsies, offers promising safety results. In one study, participants reported no serious health problems. This indicates that the system did not cause major issues for patients in that study. However, one patient experienced a pneumothorax, or collapsed lung, after a biopsy. Treatment involved a chest tube, a common method for managing this condition.

Overall, the Ion System is designed to be less invasive, typically resulting in fewer complications. However, as with any medical procedure, some risks remain.12345

Why are researchers excited about this trial?

The Ion Endoluminal System is unique because it uses advanced robotic technology to navigate the intricate pathways of the lungs for biopsies. Unlike traditional methods, which often rely on manual bronchoscopy or CT-guided needle biopsies, this system offers a minimally invasive approach with precise targeting of pulmonary lesions. Researchers are excited about this technique because it promises to improve accuracy and safety, potentially reducing the need for more invasive procedures and enhancing patient outcomes.

What evidence suggests that the Ion Endoluminal System is effective for pulmonary lesion localization or biopsy?

Research has shown that the Ion Endoluminal System, which participants in this trial may experience, effectively takes tissue samples from lung nodules. One study found that it successfully collected useful samples in 83% of cases. Known for its accuracy, the system excels at reaching difficult lung areas. During operations, Ion accurately identified non-cancerous tissues, though its ability to detect cancer was moderate. Overall, the Ion system appears promising for improving lung nodule diagnosis.34678

Who Is on the Research Team?

MP

Michael Pritchett, DO, MPH

Principal Investigator

FirstHealth of the Carolinas

JR

Janani Reisenauer, MD

Principal Investigator

Mayo Clinic

Are You a Good Fit for This Trial?

Inclusion Criteria

You are eligible for a planned lung lesion localization or biopsy procedure using the Ion Endoluminal System.
You comprehend and abide by the study regulations, as well as provide informed consent.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Procedure

Participants undergo a shape-sensing robotic-assisted bronchoscopy lung lesion localization or biopsy procedure with the Ion Endoluminal System

Intra-procedure

Follow-up

Participants are monitored for safety and effectiveness after the procedure

24 months

What Are the Treatments Tested in This Trial?

Interventions

  • Ion Endoluminal System

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: Subjects with biopsy, with or without localization, of pulmonary lesion using Ion Endoluminal SystemExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Intuitive Surgical

Lead Sponsor

Trials
80
Recruited
49,600+

Gary Guthart

Intuitive Surgical

Chief Executive Officer since 2010

PhD in Engineering, California Institute of Technology

Henry Charlton

Intuitive Surgical

Chief Medical Officer since 2023

MD from an unspecified institution

Citations

Latest Research on Ion Robotic Bronchoscopy

Examining outcomes data helps generate evidence showing the potential role of Ion endoluminal systems in the patient journey for lung nodule biopsy. Several ...

Accuracy and efficacy of Ion robotic-assisted ...

Intraoperative diagnoses performed on fine needle aspirations acquired using Ion were highly specific but showed moderate sensitivity in diagnosing malignancy.

PRECIsE Clinical Study Preliminary Results Favorable for ...

Use of the Ion system for pulmonary nodule biopsy resulted in an 83% diagnostic yield, which represents the likelihood that tissue samples obtained during the ...

Shape-sensing robotic-assisted bronchoscopy for ...

Such reports highlight the need for improved procedural outcomes for small peripheral nodules by developing new bronchoscopy tools and ...

Study Details | NCT05160571 | A Retrospective Multicenter ...

This study is a retrospective multi-center chart review of patients who underwent an attempted biopsy of one or more pulmonary lesion(s) with the Ion ...

Ion Robotic Bronchoscopy

We built Ion on the belief that collecting lung tissue samples for biopsy could be safe and simple, even when lung nodules are small and located in the ...

MAUDE Adverse Event Report: INTUITIVE SURGICAL, INC ION

It was reported that the patient underwent an ion endoluminal lung biopsy procedure and developed a pneumothorax requiring a chest tube.

Ion robotic biopsy system abbreviates lung cancer diagnosis

The Ion robotic bronchoscopy system's thin, maneuverable catheter allows clinicians to reach small lesions in all 18 segments of the lung.